Heron Therapeutics, Inc.

NasdaqCM:HRTX Stock Report

Market Cap: US$201.7m

Heron Therapeutics Past Earnings Performance

Past criteria checks 0/6

Heron Therapeutics has been growing earnings at an average annual rate of 39.8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 13.2% per year.

Key information

39.83%

Earnings growth rate

46.07%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate13.16%
Return on equity-91.22%
Net Margin-8.75%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target

Nov 08
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target

Heron Therapeutics: The View From 30,000 Feet Amid The Zynrelef Launch

Aug 25

Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 09
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
User avatar

ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access

Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.

Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop

Apr 18
Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop

Heron Therapeutics: Four Horse Race Of Approved Therapies

Mar 08

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry

Mar 01
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry

Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Sep 16

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Aug 10
Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Aug 08

Revenue & Expenses Breakdown

How Heron Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:HRTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 25155-141010
30 Jun 25150-1980
31 Mar 25149-8990
31 Dec 24144-141000
30 Sep 24138-28900
30 Jun 24136-48960
31 Mar 24132-811090
31 Dec 23127-1111200
30 Sep 23123-1201320
30 Jun 23118-1371310
31 Mar 23114-1511230
31 Dec 22108-1821440
30 Sep 2298-2171270
30 Jun 2295-2271340
31 Mar 2290-2321350
31 Dec 2186-2211270
30 Sep 2186-2281170
30 Jun 2183-2341040
31 Mar 2183-228960
31 Dec 2089-2271020
30 Sep 20103-2231000
30 Jun 20126-1981030
31 Mar 20140-1931120
31 Dec 19146-2051280
30 Sep 19140-1961260
30 Jun 19117-2011240
31 Mar 1998-1901110
31 Dec 1877-179940
30 Sep 1859-192880
30 Jun 1847-195840
31 Mar 1839-199850
31 Dec 1731-197820
30 Sep 1722-183780
30 Jun 1713-190750
31 Mar 175-190700
31 Dec 161-173690
30 Sep 160-156650
30 Jun 160-131560
31 Mar 160-110470
31 Dec 150-98360
30 Sep 150-87280
30 Jun 150-83240
31 Mar 150-79220

Quality Earnings: HRTX is currently unprofitable.

Growing Profit Margin: HRTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HRTX is unprofitable, but has reduced losses over the past 5 years at a rate of 39.8% per year.

Accelerating Growth: Unable to compare HRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (52.4%).

Return on Equity

High ROE: HRTX has a negative Return on Equity (-91.22%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 01:36
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Heron Therapeutics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Liisa BaykoCitizens JMP Securities, LLC
Joshua SchimmerEvercore ISI